A1 Biochem Research (India) Profile
Key Indicators
- Authorised Capital ₹ 13.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 13.00 Cr
as on 13-12-2024
- Company Age 2 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
About A1 Biochem Research (India)
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 13.00 Cr and a paid-up capital of Rs 13.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at A1 Biochem Research (India) Private Limited India is Hardika Trivedi as COMPANY SECRETARY. Gadikota Reddy, Narendra Gadikota, and Geetha Banda serve as directors at the Company.
- CIN/LLPIN
U24299TG2022PTC164878
- Company No.
164878
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2022
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at A1 Biochem Research (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hardika Trivedi  | Company Secretary | 06-Apr-2024 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gadikota Reddy | Director | 18-Jul-2022 | Current |
| Narendra Gadikota | Director | 18-Jul-2022 | Current |
| Geetha Banda | Director | 10-Jul-2024 | Current |
Financial Performance of A1 Biochem Research (India).
A1 Biochem Research (India) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of A1 Biochem Research (India)?
In 2023, A1 Biochem Research (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
A1 Biochem Labs (India) Private LimitedActive 3 years 2 monthsGadikota Reddy and Narendra Gadikota are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at A1 Biochem Research (India)?
Unlock and access historical data on people associated with A1 Biochem Research (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of A1 Biochem Research (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped A1 Biochem Research (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
